Boston Scientific (BSX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
Boston Scientific (BSX) reachead $100.88 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
Boston Scientific continues to successfully expand its operations across various geographies outside the United States.
Boston Scientific has the highest Composite Rating of 126 companies in the medical products industry. The post Medical Products Leader Tops These Early-Bird Buy Points appeared first on Investor's Business Daily.
In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.67, denoting a +1.97% change from the preceding trading day.
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.
Boston Scientific (BSX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?